Myocardial Infarction News and Research

RSS

Cardiologist measures risk factors associated with CR

The cardiologist Aitor Jim-nez has managed to gather and characterise in detail 110 cases of cardiac rupture (CR), after spending 22 years (1978-2000) gathering data at the Hospital de Cruces, near Bilbao. It is one of the broadest anatomical series described in this respect. CR is the most serious complication of acute myocardial infarction; it is not very common, but when it does occur, it is mortal in practically all cases. So prevention, although difficult, seems more feasible than cure.

10 Jan 2012

Cardio3BioSciences raises €3.1M in non-dilutive funding

The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.

10 Jan 2012

Research roundup: New ethics guidelines for doctors urge cost consideration; HIV testing in teens

Today's research comes from the Annals of Internal Medicine, the Journal of the American Medical Association, the Archives of Pediatrics and Adolescent Medicine, George Washington University and the Robert Wood Johnson Foundation.

7 Jan 2012

Incidence of type 2 diabetes and hypertension increases with exposure to NOx

The incidence of type 2 diabetes and hypertension increases with cumulative levels of exposure to nitrogen oxides, according to a new study led by researchers from the Slone Epidemiology Center (SEC) at Boston University.

6 Jan 2012

CRF sponsors Seventh International Conference on Cell Therapy for Cardiovascular Disease

The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Re-admission rates high among U.S. heart attack patients: Study

According to new research from U.S health experts, Americans who have a severe form of a heart attack are far more likely to be readmitted to the hospital than people from 16 other countries with the same kind of heart attack.

4 Jan 2012

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

BioLineRx, a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040), a novel medical device intended for the prevention of cardiac remodeling following an acute myocardial infarction (AMI).

4 Jan 2012

Troponin I level test may help rule-out diagnosis of heart attack

For patients admitted to an emergency department with chest pain, use of a contemporary or highly sensitive test for levels of troponin I (a protein in muscle tissue) may help rule-out a diagnosis of heart attack, while changes in the measured levels of this biomarker at 3 hours after admission may be useful to confirm a diagnosis of heart attack, according to a study in the December 28 issue of JAMA.

28 Dec 2011

Researchers identify molecules that can stimulate heart muscle regeneration

Damaged heart tissue is not known for having much inherent capacity for repair. But now, scientists are closing in on signals that may be able to coax the heart into producing replacement cardiac muscle cells. Using a zebrafish model system, researchers have identified a family of molecules that can stimulate stem cells to develop into beating heart muscle cells.

23 Dec 2011

Abbott commences Absorb-XIENCE PRIME comparative clinical trial

Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

9 Dec 2011

Research roundup: Recession's big impact on men's insurance coverage

Researchers examined three sets of surveillance data and found that of the estimated 1.2 million persons in the United States living with the human immunodeficiency virus, 942,000 persons were aware of their infection. More than three-quarters of those were "linked to care" and among HIV-infected adults in care, "45 percent received prevention counseling, and 89 percent were prescribed antiretroviral therapy."

3 Dec 2011

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

1 Dec 2011

Most heart attack patients not transported quickly enough for angioplasty

Most heart attack patients transferred between hospitals for the emergency artery-opening procedure called angioplasty are not transported as quickly as they should be, Yale School of medicine researchers report in the first national study of "door-in door-out" time for transfer patients.

29 Nov 2011

Infarct size associated with time of day onset of ischemia

The size of a heart attack and subsequent left-ventricular function are significantly different based on the time of day onset of ischemia, according to a first of its kind study in humans, published online Nov. 17 in Circulation Research.

22 Nov 2011

CRF to sponsor Women's Heart Health Summit

The Cardiovascular Research Foundation (CRF) will sponsor the Women's Heart Health Summit: "In Pursuit of Excellence: Improving Cardiovascular Outcomes in Women." The goal of the meeting is to examine current prevention, treatment, and key research issues to collectively identify opportunities and recommendations that will lead to improved cardiovascular outcomes in women.

22 Nov 2011

Research roundup: The effect of heart drug costs; Doctors' financial incentives when ordering stress tests

The researchers examined whether drug costs for heart attack patients affects health. Half of a group of more than 5,000 patients were given prescription coverage that eliminated co-payments and expanded drug choices. The others had "usual prescription coverage."

18 Nov 2011